This study aimed to evaluate patients with RRMM who underwent daratumumab (DARA) therapy. This multicenter and retrospective study included 134 patients who underwent at least two courses of DARA from February 01, 2018 to April 15, 2022. Epidemiologic, disease and treatment characteristics of patients and, treatment related side effects were evaluated. Survival analysis were performed. The median age at initiation of DARA therapy was 60 (35-88) years. The median time to initiation of DARA and the median follow-up time were 41.2 (5.1-223) and 5.7 (2.1-24.1) months, respectively. The ORR after DARA therapy was 75 (55.9%), and ≥VGPR was observed in 48 (35.8%) patients. Overall survival (OS) and progression-free survival (PFS) for all patients were 11.6 (7.8-15.5) and 8.0 (5.1-10.9) months, respectively. OS was higher for patients undergoing DARA-Vd than for those undergoing DARA-Rd (16.9 vs. 8.3 months; p=0.014). Among patients undergoing Dara-Rd, PFS was higher in those without EMD (EMD-) than those with EMD (EMD+)(NA vs. 3.7 months; OR, 3.4; p < 0.001). The median number of prior therapies was 3 (1-8). Initiation of DARA therapy in the early period provides OS and PFS advantage, although statistically insignificant. Infusion-related reactions were observed in 18 (13.4%) patients. All reactions occurred during the first infusion and most reactions were grade 1-2 (94.5%). The frequency of neutropenia and thrombocytopenia was higher in the DARA-Rd group (61.9% vs. 24.7%; p < 0.001 and 42.9% vs. 15.7%; p < 0.001). Our study reflects real-life data in terms of DARA therapy for patients with RRMM and supports the early initiation of DARA therapy.
Introduction: Pulmonary fibrosis is a progressive and life-threatening condition frequently associated with chemotherapeutic agents, such as bleomycin (BLE). Aronia melanocarpa extract (AME), a potent antioxidant derived from black chokeberry, has shown promising anti-inflammatory and anti-fibrotic effects in various pre-clinical models. Objective: This study aims to evaluate the protective and therapeutic effects of AME in a rat model of BLE-induced pulmonary fibrosis. Methods: A total of 60 rats were divided into six groups: control, fibrosis (BLE only), positive control (BLE + methylprednisolone), AME-only, AME + BLE (AME administered concurrently with BLE), and BLE + AME (AME administered after fibrosis induction). Lung tissues were analyzed histologically and biochemically for inflammation, fibrosis, and oxidative stress markers. Results: AME administration significantly reduced alveolar wall thickening, hemorrhage, cellular infiltration, and collagen deposition. These effects were more pronounced in the AME + BLE group, indicating a potential prophylactic advantage. In addition, AME restored antioxidant enzyme levels and suppressed lipid peroxidation. Conclusion: AME exhibits both preventive and therapeutic effects against BLE-induced lung injury. Its polyphenol-rich composition and antioxidative properties support its potential as a low-cost, low-toxicity candidate in pulmonary fibrosis management.
Objective: The study aimed to evaluate the clinical effects of levofloxacin (LEVO) and moxifloxacin (MOXI) prophylaxis during the treatment of acute myeloid leukemia (AML). Methods: This study had a prospective observational design and included AML patients who were scheduled for standard remission-induction (RI) or consolidation (C) chemotherapy. Prophylactic LEVO or MOXI was started at a ratio of 1:1 when neutropenia developed, and two groups were created. The primary endpoint was the frequency of febrile neutropenia (FN) and the time to FN. Results: 120 patients (60 patients in each group) were enrolled in the study. The frequency of FN tended to be higher in the LEVO group but was statistically insignificant (82.1% vs. 75.5%; p=0.702). The time to FN was 10.8±5.7 days and 10.1±5.7 days in the LEVO and MOXI groups, respectively (p=0.393). Microorganisms were izolated in 50.8% of patients who developed FN. The documented infection and bacteremia rate tended to be higher in the MOXI group (71.1% vs. 56.6%; p=0.331 and 87.5% vs. 80.5%; p=0.906). The rates of quinolone resistance were 69.2% and 75% in the LEVO and MOXI groups, respectively (p=0.451). The frequency of FN was higher during the RI phase than the C phase (89.1% vs. 70%; p=0.010). The frequency of documented infection was higher during the C phase than during the RI phase (77.1% vs. 49.1%; p=0.008). Conclusion: This study showed that prophylactic MOXI and LEVO have similar efficacy in AML patients.
Introduction Ruxolitinib is a JAK1/2 inhibitor used in patients with polycythemia vera (PV) who are resistant or intolerant to hydroxyurea. Although it effectively controls hematologic parameters, its immunosuppressive nature may predispose patients to infectious and immune-mediated complications. Here, we report a rare case of concurrent hepatitis B virus (HBV) reactivation and warm autoimmune hemolytic anemia (wAIHA) during ruxolitinib treatment. Case presentation A 58-year-old male was diagnosed with PV based on erythrocytosis (Hb: 22.9 g/dL), low erythropoietin level (1.3 mIU/mL), splenomegaly (176 mm), and a JAK2 V617F mutation detected in both peripheral blood and bone marrow. Hydroxyurea was initiated due to inadequate hematocrit control despite phlebotomies but was ineffective. Ruxolitinib was introduced and later escalated to 15 mg twice daily, achieving target hematologic response. In the 14th month of therapy, the patient developed anemia, transaminase elevation, hyperbilirubinemia, and HBV reactivation (HBsAg, HBeAg, anti-HBe positive; HBV DNA: 772,066 IU/mL). Further evaluation revealed hemolytic anemia with positive direct Coombs test, low haptoglobin, reticulocytosis, and elevated LDH. Management and outcome Ruxolitinib was discontinued, and entecavir plus oral corticosteroids were initiated. Clinical and laboratory findings improved, allowing ruxolitinib to be safely reintroduced at a lower dose after 1 month. Corticosteroids were tapered without recurrence, and the patient remains clinically stable under maintenance therapy. Conclusion This case highlights the potential for dual immune complications, HBV reactivation and wAIHA, during ruxolitinib therapy in PV. Careful pre-treatment screening and close monitoring are essential for early detection and management of such adverse events. This case underscores the importance of pre-treatment HBV screening and vigilant monitoring for immune complications during ruxolitinib therapy.